About VerImmune
VerImmune is a company based in Baltimore (United States) founded in 2019 by John Troyer and Joshua Wang. VerImmune has raised $10.13 million across 4 funding rounds from investors including Beiley Biofund, Proxima Ventures and Mana Ventures. VerImmune offers products and services including Anti-Tumor Immune Redirection (AIR). VerImmune operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Baltimore, United States
- Founders John Troyer, Joshua Wang
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Verimmune, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.13 M (USD)
in 4 rounds
-
Latest Funding Round
$4.5 M (USD), Seed
Sep 23, 2024
-
Investors
Beiley Biofund
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of VerImmune
VerImmune offers a comprehensive portfolio of products and services, including Anti-Tumor Immune Redirection (AIR).
Therapy redirects immune memory to target and destroy cancer cells.
Funding Insights of VerImmune
VerImmune has successfully raised a total of $10.13M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $4.5 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in VerImmune
VerImmune has secured backing from 9 investors, including venture fund and angel investors. Prominent investors backing the company include Beiley Biofund, Proxima Ventures and Mana Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in biotechnology startups is facilitated by Beiley Biofund.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments in early-stage tech firms and consumer brands are made.
|
Locked | Locked | Locked |
Investor details for VerImmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VerImmune
Investment portfolio details for VerImmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - VerImmune
Detailed financials for VerImmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Verimmune Comparisons
Peer comparison for VerImmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of VerImmune
VerImmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of VerImmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Verimmune
Complete news archive for VerImmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VerImmune
VerImmune was founded in 2019 and raised its 1st funding round 1 year after it was founded.
VerImmune is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Joshua Wang is the current CEO of VerImmune. They have also founded this company.
VerImmune is a funded company, having raised a total of $10.13M across 4 funding rounds to date.
VerImmune was founded in 2019 in Baltimore, United States, as a biotechnology firm focused on oncology. Vaccines for cancer treatment are developed through Anti-tumor Immune Redirection (AIR) technology, by which pre-existing immune memory from childhood vaccines or infections is redirected against tumors. A papillomavirus nanoparticle conjugated with viral antigens has been created to support this approach. Operations center on advancing these therapeutic innovations.
VerImmune's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
VerImmune offers Anti-Tumor Immune Redirection (AIR).
VerImmune has 9 investors. Key investors include Beiley Biofund, Proxima Ventures, Mana Ventures, Gaingels, and John Ballantyne.